United Therapeutics Corporation Company Profile (NASDAQ:UTHR)

United Therapeutics Corporation trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics Corporation announced that its Board of Directors has authorized a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

United Therapeutics Corporation (NASDAQ:UTHR) announced its quarterly earnings data on Thursday, July, 27th. The company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to analysts' expectations of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $4.42 EPS. View United Therapeutics Corporation's Earnings History.

United Therapeutics Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for United Therapeutics Corporation.

11 brokers have issued 12 month price objectives for United Therapeutics Corporation's stock. Their predictions range from $95.00 to $213.00. On average, they expect United Therapeutics Corporation's share price to reach $134.70 in the next twelve months. View Analyst Ratings for United Therapeutics Corporation.

Here are some recent quotes from research analysts about United Therapeutics Corporation stock:

• 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Also, recently, the company announced that regulatory issues will delay the U.S. launch of RemoSynch. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. Shares also underperformed the industry this year so far. Estimates have remained stable ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (10/9/2017)
• 2. Cowen and Company analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
• 3. Credit Suisse Group analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
• 4. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
• 5. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)

Some companies that are related to United Therapeutics Corporation include Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), ICON PLC (ICLR), Exact Sciences Corporation (EXAS), INC Research Holdings (INCR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Ligand Pharmaceuticals Incorporated (LGND).

United Therapeutics Corporation's management team includes the folowing people:

• Martine A. Rothblatt Ph.D. J.D., Chairman of the Board, Chief Executive Officer
• Michael Benkowitz, President, Chief Operating Officer
• Christopher Patusky J.D., Lead Independent Vice Chairman of the Board
• James C. Edgemond, Chief Financial Officer, Treasurer
• Paul A. Mahon J.D., Executive Vice President, General Counsel, Corporate Secretary
• Raymond A. Dwek, Non-Independent Director
• Christopher Causey, Independent Director
• Richard A. Giltner, Independent Director
• Katherine J. Klein Ph.D., Independent Director
• Raymond C. Kurzweil J.D., Independent Director

United Therapeutics Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (1.50%), Robeco Institutional Asset Management B.V. (0.36%), Mutual of America Capital Management LLC (0.08%), Shell Asset Management Co. (0.08%), State Treasurer State of Michigan (0.04%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own United Therapeutics Corporation stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics Corporation.

United Therapeutics Corporation's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Meeder Asset Management Inc., Mutual of America Capital Management LLC and Fisher Asset Management LLC. Company insiders that have sold United Therapeutics Corporation stock in the last year include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics Corporation.

United Therapeutics Corporation's stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Robeco Institutional Asset Management B.V., Shell Asset Management Co. and Assenagon Asset Management S.A.. View Insider Buying and Selling for United Therapeutics Corporation.

Shares of United Therapeutics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of United Therapeutics Corporation stock can currently be purchased for approximately $121.01.